Facet Biotech (Facet) and Bristol-Myers Squibb have reported positive data from a phase I/II study of Elotuzumab, an investigational humanised antibody being studied for the treatment of relapsed
Genzyme has presented data from its CAM314 randomised Phase 3 clinical trial comparing Campath (alemtuzumab) in combination with Fludara (fludarabine phosphate) (FluCAM) to Fludara alone in patients with
Alethia Biotherapeutics (Alethia) has obtained the exclusive worldwide diagnostic rights to a peptide that specifically binds to tumor-associated clusterin from the National Research Council Biotechnology Research Institute (NRC-BRI)
MicroPhage has obtained CE Mark to market in Europe the first of its instrument-free, rapid tests based on its patented Bacteriophage amplification technology. The company’s initial commercial product
Pediapharm has launched EpiCeram, a skin barrier emulsion indicated for atopic dermatitis and other dry skin conditions. Earlier this year, Pediapharm had announced an agreement with Ceragenix Pharmaceuticals
The Dow Chemical has formed a new independent company known as Pfenex through its Dow Venture Capital group. The new company, headquartered in San Diego, California, is based
Novo Nordisk has initiated its first Phase 1 clinical trial with an oral insulin analogue (NN1952). This milestone releases a $2m payment to Merrion whose Gipet technology is
Johnson & Johnson Pharmaceutical Research and Development (Johnson & Johnson) has reported results from the Phase III Einstein-Extension (EXT) clinical trial of the oral anticoagulant Rivaroxaban, which showed
Pharmacyclics has reported interim results from a Phase I/II study showing safety and clinical activity in patients with relapsed / recurrent non-hodgkin’s lymphoma (NHL) treated with its HDAC
ImmunoGen has reported positive clinical data with IMGN901 candidate in the treatment of relapsed and relapsed/refractory multiple myeloma (MM), including prolonged benefit in patients whose disease had progressed
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.